How Do Cost-Effectiveness Analyses Inform Reimbursement Decisions for Oncology Medicines in Canada? The Example of Sunitinib for First-Line Treatment of Metastatic Renal Cell Carcinoma-Reference-Cited by-同舟云学术

How Do Cost-Effectiveness Analyses Inform Reimbursement Decisions for Oncology Medicines in Canada? The Example of Sunitinib for First-Line Treatment of Metastatic Renal Cell Carcinoma

Published:2010-09 Issue:6 Volume:13 Page:837-845
ISSN:1098-3015
Container-title:Value in Health
language:en
Short-container-title:Value in Health

Author:

Chabot Isabelle,Rocchi Angela

Publisher

Elsevier BV

Subject

Public Health, Environmental and Occupational Health,Health Policy

Reference60 articles.

1. The role of economic evidence in Canadian oncology reimbursement decision-making: to lambda and beyond;Rocchi;Value Health,2008

2. Epidemiology of renal-cell carcinoma;Tavani;J Nephrol,1997

3. Renal cell carcinoma: current status and future prospects;Drucker;Cancer Treat Rev,2005

4. Metastatic renal cell carcinoma;Flanigan;Curr Treat Options Oncol,2003

Cited by 33 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cost-Effectiveness Analysis Comparing Biopsy in Advance of Ablation with Concurrent Biopsy and Ablation for Small Renal Masses Measuring 1–3 cm;Journal of Vascular and Interventional Radiology;2024-09

2. Cost-Effectiveness of Brentuximab Vedotin Versus Physician’s Choice of Methotrexate or Bexarotene for the Treatment of Cutaneous T-cell Lymphoma in Canada;Advances in Therapy;2023-03-15

3. Cost-effectiveness of brentuximab vedotin plus chemotherapy for previously untreated CD30-positive peripheral T-cell lymphoma in Canada;Journal of Medical Economics;2022-03-07

4. An updated cost-effectiveness analysis of pazopanib versus sunitinib as first-line treatment for locally advanced or metastatic renal cell carcinoma in Italy;Journal of Medical Economics;2020-11-05